Nitroaspirins and morpholinosydnonimine but not aspirin inhibit the formation of superoxide and the expression of gp91phox induced by endotoxin and cytokines in pig pulmonary artery vascular smooth muscle cells and endothelial cells

Circulation

Volumn 110, Issue 9, 2004, Pages 1140-1147

  Muzaffar, Saima ^a   Shukla, Nilima ^a   Angelini, Gianni ^a   Jeremy, Jamie Y ^a,b  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b BRISTOL ROYAL INFIRMARY   (United Kingdom)

Author keywords

NADPH oxidase; Nitric oxide; Pulmonary artery; Respiratory distress syndrome, adult; Superoxides

Indexed keywords

2 ACETOXYBENZOATE 2 (2 NITROXY)BUTYL ESTER; 2 ACETOXYBENZOATE 2 (2 NITROXYMETHYL)PHENYL ESTER; ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID 3 (NITROXYMETHYL)PHENYL ESTER; APOCYNIN; CYTOCHROME C; CYTOKINE; DIPHENYLIODONIUM SALT; ENDOTOXIN; ENZYME INHIBITOR; GLYCOPROTEIN GP 91; GUANYLATE CYCLASE INHIBITOR; INTERLEUKIN 1ALPHA; LINSIDOMINE; LIPOPOLYSACCHARIDE; NCX 4040; NCX 4050; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OXADIAZOLOQUINOXALINONE; PROSTACYCLIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT RESPIRATORY DISTRESS SYNDROME; ANIMAL CELL; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIUM CELL; ENZYME ACTIVITY; GENE EXPRESSION; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PULMONARY ARTERY; PULMONARY ARTERY ENDOTHELIAL CELL; PULMONARY ARTERY VASCULAR SMOOTH MUSCLE CELL; SWINE; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING;

ACETOPHENONES; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; DRUG EVALUATION, PRECLINICAL; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; ENZYME INDUCTION; EPOPROSTENOL; GLYCOPROTEINS; GUANYLATE CYCLASE; INTERLEUKIN-1; LIPOPOLYSACCHARIDES; MALE; MOLSIDOMINE; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NADPH OXIDASE; NITRIC OXIDE; NITRIC OXIDE DONORS; NITRO COMPOUNDS; ONIUM COMPOUNDS; PULMONARY ARTERY; RESPIRATORY DISTRESS SYNDROME, ADULT; SUPEROXIDES; SUS SCROFA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 4344677822     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000139851.50067.E4     Document Type: Article

References (24)

1. Chabot F, Mitchell JA, Guttendge JM, et al. Reactive oxygen species in acute lung injury. Eur Respir J. 1998;11:745-757.
2. Weinacker AB, Vaszar LT. Acute respiratory distress syndrome: physiology and new management strategies. Annu Rev Med. 2001;52: 221-237.
3. Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med. 2000;342:1334-1349.
4. Stuart-Smith K, Jeremy JY. Microvessel damage in acute respiratory distress syndrome: the answer may not be NO. Br J Anaesth. 2001;87: 272-279.
5. Pittet J-F, Mackersie RC, Martin TR, et al. Biological markers of acute lung injury: prognostic and pathogenetic significance (state of art). Am J Respir Care Med. 1997;155:1187-1205.
6. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res. 2000;86:494-501.
7. Muzaffar S, Jeremy JY, Angelini GD, et al. The role of the endothelium and nitric oxide synthases in modulating superoxide formation induced by endotoxin and cytokines in porcine pulmonary arteries. Thorax. 2003;58: 598-604.
8. Brower RG, Ware LB, Berthiaume Y, et al. Treatment of ARDS. Chest. 2001;120:1347-1367.
9. Bernard GR, Wheeler AP, Russell JA, et al. The effects of ibuprofen on the physiology and survival of patients with sepsis. N Engl J Med. 1997;336:912-918.
10. Lowson SM. Inhaled alternatives to nitric oxide. Anesthesiology. 2002; 96:1504-1513.
11. 2α and cytokines. Br J Pharmacol. 2004;141:488-496.
12. Klinger JR. Inhaled nitric oxide in ARDS. Crit Care Clin. 2002;18: 45-68.
13. Jeremy JY, Rowe D, Emsley AM, et al. Nitric oxide and the proliferation of vascular smooth muscle cells. Cardiovasc Res. 1999;43:580-594.
14. Jeremy JY, Mehta D, Bryan AJ, et al. Platelets and saphenous vein graft failure following coronary artery bypass surgery. Platelets. 1997;8:295-309.
15. Del Soldato P, Sorrentino R, Pinto A. NO-aspirins: a class of new anti-inflammatory and anti-thrombotic agents. Trends Pharmacol Sci. 1999;20:319-323.
16. Southgate KM, Davies M, Booth RF, et al. Involvement of extracellular-matrix-degrading metalloproteinases in rabbit aortic smooth-muscle cell proliferation. Biochem J. 1992;288:93-99.
17. Meyrick BO, Ryan US, Brigham KL. Direct effects of E coli endotoxin on structure and permeability of pulmonary endothelial monolayers and the endothelial layer of intimal explants. Am J Pathol. 1986;122: 140-151.
18. Brown AS, Moro MA, Masse JM, et al. Nitric oxide-dependent and independent effects on human platelets treated with peroxynitrite. Cardiovasc Res. 1998;40:380-388.
19. Bauer TT, Monton C, Torres A, et al. Comparison of systemic cytokine levels in patients with acute respiratory distress syndrome, severe pneumonia, and controls. Thorax. 2000;55:46-52.
20. Ignarro LJ. Physiology and pathophysiology of nitric oxide. Kidney Int. 1996;55:2-5.
21. Zouki C, Zhang SL, Chan JS, et al. Peroxynitrite induces integrin-dependent adhesion of human neutrophils to endothelial cells via activation of the Raf-1/MEK/Erk pathway. FASEB J. 2001;15:25-27.
22. Zou MH, Ullrich V. Peroxynitrite formed by simultaneous generation of nitric oxide and superoxide selectively inhibits bovine aortic prostacyclin synthase. FEBS Lett. 1996;382:101-104.
23. Reines HD, Halushka PV, Cook JA, et al. Plasma thromboxane concentrations are raised in patients dying with septic shock. Lancet. 1982;2: 174-175.
24. Petros A, Bennett D, Vallance P. Effect of nitric oxide synthase inhibitors on hypotension in patients with septic shock. Lancet. 1991;338: 1557-1558.